Skip to main content

Table 1 Population (n = 53) and Tumor (n = 100) characteristics

From: Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience

Characteristic

N (%)

Patient Sex

 Male

34 (64.2)

 Female

19 (35.9)

Patient age at diagnostic (years)

 Median (interquartile range)

61 (20–84)

Patient age at Radiofrequency ablation treatment (RFA) (years)

 Median (interquartile range)

67 (29–86)

Treatment before RFA (per patient)

28 (53)

 Interferon

18 (34)

 Sunitinib

9 (17)

 Sorafenib

1 (2)

Primary histology (per patient)

 Clear cell carcinoma

48 (90)

 Papillary carcinoma

1 (2)

 Mucinous tubular renal cell carcinoma RCC missing information

1 (2)1 (2)

 Sarcomatoid component (10%)

2 (4)

T staging (per patient)

 T1 – T2

19 (36)

 T3 – T4

25 (47)

 Unknown

9 (17)

Tumor size in mm (per lesion)

  < 10

32 (32)

 10 < x < 20

43 (43)

 20 < x < 30

15 (15)

  ≥ 30

9 (9)

 missing

1 (1)

Time to metastasis (months)

 Median (interquartile range)

22 (7–53)

Number of metastases (per patient)

 1

25 (47)

 2

11 (21)

 3

9 (17)

 4–6

8 (15)

Number of RFA treatments (per patient)

 1

41 (77)

 2

12 (23)

Fuhrman grade (per patient)

 1

1 (2)

 2

9 (17)

 3

26 (49)

 4

5 (9)

 Unknown

2 (3)

Time to recurrence (all types, per patient)

  ≤ 12 months

20 (38)

  > 12 months

33 (62)

Concomitant metastases (per patient)

 Concomitant

10 (19)

 Delayed

43 (81)